Patents by Inventor Robert N. Palmer

Robert N. Palmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • System for luminescing and propelling a projectile
    Patent number: 7900619
    Abstract: A projectile having light emitting structure and a rechargeable power source is launched by projectile launching apparatus such as a gun. The projectile launching apparatus charges the rechargeable power source and when the projectile is propelled a visual display is produced by the lighted propelled projectile.
    Type: Grant
    Filed: February 6, 2008
    Date of Patent: March 8, 2011
    Assignee: Sierra Innotek, Inc.
    Inventors: William R. Palmer, Stephen L. Palmer, Robert N. Palmer
  • Device for providing internal illumination of live flowers and other products
    Patent number: 7278752
    Abstract: A small light source for internally illuminating live flowers and other products is formed in the shape of a pin with a battery case operatively connected to the light source. A sharp penetrating tip surrounds the light source and is fixed to a rigid tube for manipulating the device to insert the light source within the structure of the plant. The device is of such a size that it can be supported by a plant without deformation of the plant.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: October 9, 2007
    Assignee: Chemical Light Inc.
    Inventors: William R. Palmer, Stephen L. Palmer, Robert N. Palmer
  • Extended release formulations of erythromycin derivatives
    Patent number: 6872407
    Abstract: Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cmax in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: March 29, 2005
    Assignee: Abbott Laboratories
    Inventors: Gerard F. Notario, Robert N. Palmer, Richard C. Hom, Jie Zhang, Karen J. Devcich, Susan J. Semla
  • Extended release formulations of erythromycin derivatives
    Publication number: 20030133981
    Abstract: Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cmax in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
    Type: Application
    Filed: November 22, 2002
    Publication date: July 17, 2003
    Inventors: Gerard F. Notario, Robert N. Palmer, Richard C. Hom, Jie Zhang, Karen J. Devcich, Susan J. Semla
  • Extended release formulations of erythromycin derivatives
    Patent number: 6551616
    Abstract: Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cmax in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: April 22, 2003
    Assignee: Abbott Laboratories
    Inventors: Gerard F. Notario, Robert N. Palmer, Richard C. Hom, Jie Zhang, Karen J. Devcich, Susan J. Semla